Business
Amgen Announces New Data Being Presented At ASH 2021
BLINCYTO® (blinatumomab) Data Demonstrate Superior Overall Survival in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia in Longer Follow-up of
About this update from Amgen Inc.
[{"type":"text","content":"BLINCYTO® (blinatumomab) Data Demonstrate Superior Overall Survival in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia in Longer Follow-up of Phase 3 Trial\n First Presentation of Efficacy and Safety Data With Subcutaneous BLINCYTO Administration in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia\n\n\nTHOUSAND OAKS, Calif., Dec. 6, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, and virtually, from Dec. 11-14, 2021. \n\"The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers,\" said David M. Reese, M.D., executive vice president of Research and Development at Amgen. \"By accelerating the development and delivery of transformative medicines in difficult to treat and vulnerable patient populations, including children and pregnant women, we continue to focus on the relentless pursuit of breakthroughs for blood cancer patients and their families.\" \nAmgen will present data on its bispecific T-cell engager (BiTE®) platform, including BLINCYTO® (blinatumomab), as well as KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Updated data from the Phase 3 '215 trial in children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) showed BLINCYTO improved event-free survival (EFS) and overall survival (OS) versus chemotherapy before allogeneic hematopoietic stem cell transplant (alloHSCT). The first presentation of safety and efficacy data with BLINCYTO administered subcutaneously in adults with relapsed or refractory B-ALL also demonstrated encouraging results. \nAdditionally, results from the Phase 1b study investigating KYPROLIS in combination with vincristine, dexamethasone, PEG-asparaginase, daunorubicin (VXLD) induction therapy in children with relapsed or refractory ALL showing promising efficacy in highly advanced relapsed/refractory pediatric ALL will be presented in a poster discussion session. Analyses from the Pregnancy Surveillance Program (PSP) evaluating pregnancy and fetal outcomes of women ...